The following protocol has been designed to investigate the extent of infection, as determined by seropositivity in the general population, in any country in which COVID-19 virus infection has been reported. Each country may need to tailor some aspects of this protocol to align with public health, l...aboratory and clinical systems, according to capacity, availability of resources and cultural appropriateness. However, using a standardized protocol such as this one below, epidemiological exposure data and biological samples can be systematically collected and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different settings globally for timely estimates of COVID-19 virus infection severity and attack rates, as well as to inform public health responses and policy decisions. This is particularly important in the context of a novel respiratory pathogen, such as COVID-19 virus
more
Orientações provisórias
20 de Março de 2020
Rapporto ISS COVID-19, n. 5/2020
Gruppo di Lavoro ISS Ambiente e Qualità dell’Aria Indoor
versione del 23 marzo 2020
To save the lives of mothers and their babies, mitigate complications, and limit the spread of disease, it is critical that recommendations are made on the prevention, treatment, and surveillance of women who are exposed to EVD, acquire EVD during pregnancy or breastfeeding, or survive EVD with ongo...ing pregnancies. These guidelines are the first to provide such recommendations.
more
Orientações provisórias23 de Abrilde2020
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Ebola virus disease (EVD) after visiting or working in an area that is affected by EVD; also covered is ...occupational exposure to the disease
more
WHO published interim guidelines on the prevention of sexual transmission of Zika virus in September 2016 (1), based on a limited amount of evidence under an emergency process during a public health emergency of international concern. The body of evidence has grown considerably since then and WHO e...xperts concluded, at a meeting in March 2017, that the guidelines should be developed under the formal WHO guideline process (2).
These guidelines contain updated recommendations on the prevention of sexual transmission of Zika virus, based on the best available evidence as of June 2018.
more
Cependant depuis le début du mois de décembre, une augmentation importante de l’incidence des nouveaux cas est observée particulièrement le long du corridor vers le grand centre urbain de Butembo (zones de santé de Butembo et Katwa) et au-delà dans la zone de santé de Kayna située à envir...on 150 km de Goma. Par ailleurs, des foyers actifs ont émergé vers le nord notamment dans les zones de santé de Komanda et Oicha.
more